Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Obrador, G. T.
Right arrow Articles by Pereira, B. J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Obrador, G. T.
Right arrow Articles by Pereira, B. J. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 44-46
© 2002 European Renal Association-European Dialysis and Transplant Association


Anaemia of chronic kidney disease: an under-recognized and under-treated problem

Gregorio T. Obrador1,2 and Brian J. G. Pereira1,

1 Division of Nephrology, New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA and 2 Universidad Panamericana School of Medicine, Mexico City, Mexico

Abstract

Patients with chronic kidney disease (CKD) almost invariably develop anaemia, which is associated with increased morbidity and mortality, and reduced quality of life. Anaemia begins early in the course of CKD, and although treatment with erythropoietin is effective, the condition is often under-treated. Because of the growing body of scientific literature on the significant morbidity and mortality associated with anaemia of CKD, a Renal Anaemia Management Period (RAMP) was proposed. This is defined as the time after onset of CKD when anaemia develops and requires early diagnosis and treatment. The RAMP was developed to call attention to the need to improve outcomes for patients with CKD and possibly lower the economic burden by correcting anaemia earlier. It is an important opportunity for preventive care and has the potential to limit costs associated with comorbidities of CKD.

Keywords: anaemia; chronic kidney disease; erythropoietin; Renal Anaemia Management Period

Notes

Correspondence and offprint requests to: Dr Brian J. G. Pereira, New England Medical Center, Box 5224, 750 Washington Street, Boston, MA 02111, USA. Email: bpereira{at}lifespan.org


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
K. J. Martin and on behalf of the Epoetin Delta 3001 Study Group
Epoetin delta in the management of renal anaemia: results of a 6-month study
Nephrol. Dial. Transplant., October 1, 2007; 22(10): 3052 - 3054.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.